CTIS2023-507280-18-00招募中1 期
J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5) - J2A-MC-GZGW
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have Type 2 Diabetes (T2D), Be taking a consistent dose of diabetes drug by injection for at least 3 months., May be taking up to 2 diabetes drugs by mouth for at least 3 months., Have a high blood sugar.
排除标准
- •Have Type 1 diabetes., Have history of an inflamed pancreas (pancreatitis)., Have history of an inflamed liver (hepatitis)., Have congestive heart failure.
研究者
相似试验
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)Overweight, Obesity, Type 2 DiabetesCTIS2022-502837-24-00Eli Lilly & Co.1,460
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Obesity, Overweight, Overweight or ObesityCTIS2022-502839-19-00Eli Lilly & Co.3,000
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
进行中（未招募）
1 期
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerProstate CancerCTIS2023-506777-36-00Eli Lilly & Co.304